TME PHARM.CONF.IPO EO 1- (F:0N6A) — Market Cap & Net Worth
Market Cap & Net Worth: TME PHARM.CONF.IPO EO 1- (0N6A)
TME PHARM.CONF.IPO EO 1- (F:0N6A) has a market capitalization of $6.88 Million (€5.89 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #27903 globally and #2417 in its home market, demonstrating a -8.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TME PHARM.CONF.IPO EO 1-'s stock price €0.07 by its total outstanding shares 94091417 (94.09 Million).
TME PHARM.CONF.IPO EO 1- Market Cap History: 2018 to 2026
TME PHARM.CONF.IPO EO 1-'s market capitalization history from 2018 to 2026. Data shows change from $10.65 Billion to $7.74 Million (-65.04% CAGR).
TME PHARM.CONF.IPO EO 1- Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TME PHARM.CONF.IPO EO 1-'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0N6A by Market Capitalization
Companies near TME PHARM.CONF.IPO EO 1- in the global market cap rankings as of June 19, 2026.
Key companies related to TME PHARM.CONF.IPO EO 1- by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
TME PHARM.CONF.IPO EO 1- Historical Marketcap From 2018 to 2026
Between 2018 and today, TME PHARM.CONF.IPO EO 1-'s market cap moved from $10.65 Billion to $ 7.74 Million, with a yearly change of -65.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.74 Million | +11.75% |
| 2025 | €6.93 Million | -8.30% |
| 2024 | €7.56 Million | -70.13% |
| 2023 | €25.30 Million | -80.83% |
| 2022 | €132.00 Million | -94.47% |
| 2021 | €2.39 Billion | -66.67% |
| 2020 | €7.16 Billion | +10.34% |
| 2019 | €6.49 Billion | -39.05% |
| 2018 | €10.65 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of TME PHARM.CONF.IPO EO 1- was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.88 Million USD |
| MoneyControl | $6.88 Million USD |
| MarketWatch | $6.88 Million USD |
| marketcap.company | $6.88 Million USD |
| Reuters | $6.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more